S100A9 and hepatocellular carcinoma: Considering these challenges, it may relevant to develop therapies targeting the downstream genes and pathways dysregulated by aberrant NF-κB signaling, such as LINC00665 and S100A9, among others, rather than employing pan-inhibitory NF-κB strategies in HBV-related HCC (54).